CLINICAL_TRIALS
trial_result
· 2020-03-31
Clinical Trial Update: Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients [Phase 3]
Summary
A Phase 3 trial evaluating the efficacy and safety of lanreotide autogel at 60, 90, or 120 mg in patients with acromegaly has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ipsen | Conditions: Acromegaly | Phase 3 | Status: COMPLETED